Affluent Medical Announces Significant Clinical Milestones with Two of Its Innovative Devices: ARTUS & KALIOS
Affluent Medical, a new French medtech player specializing in innovative, minimally invasive implants designed to restore key physiological functions for patients suffering from heart and vascular diseases, as well as urinary incontinence, today announces significant clinical milestones for two of its innovative devices: ARTUS & KALIOS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180601005256/en/
Kalios (Photo: Affluent Medical)
“We are excited about these key milestones since these studies are part of Affluent Medical’s clinical development plan, aiming at obtaining CE marking for each of our four products -KARDIOZIS, KALIOS, EPYGON and ARTUS, between the end of year 2020 / year 2022”, said Daniele Zanotti Affluent Medical’s CEO.
Successful start of the clinical trial with its ARTUS urinary implant
Affluent Medical has received authorization from the French regulatory agency on medical devices2 to carry out its first clinical trial in France. This clinical trial aims at demonstrating the safety and effectiveness of its urinary implant, ARTUS. This device intends on helping men and women suffering from severe urinary incontinence to recover full control of their bladders.
A similar clinical trial is already under way in the Czech Republic. ARTUS has been implanted in a first patient at the end of May 2018, at the Cochin Hospital. In this clinical trial, ARTUS will be temporarily implanted in a total of three women.
The clinical trial, entitled “Feasibility of the implantation of the ARTUS Artificial Urinary Sphincter in women,” in conducted at the Cochin Hospital in Paris. The ARTUS artificial urinary sphincter will be temporarily inserted in three women who have undergone a full urogenital tract ablation because of bladder cancer. The goal of the study is to verify, in the first place, that it is still possible to insert a catheter inside the bladder once the implant is in place. The study also aims at demonstrating the easy implementation and effectiveness of the device (adaptation to the neck of the bladder and activation of the implant).
ARTUS is an artificial urinary sphincter intended for both men and women. Fully concealable and easy to use via remote control, ARTUS will bring more comfort to patients by granting them easy control over their everyday urinary flow. Thanks to its optimized and adjustable pressure profile on the urethra, this device reduces the risk of decreased blood flow and tissue erosion of the urethra — two major complications experienced by patients with the artificial urinary sphincters currently available on the market.
A significant under-treated medical issue
Urinary incontinence affects one in four adults, with a female prevalence of 95%3. Yet, few implants are designed to help women recover control of their bladder. Men who have had their prostates removed or are treated for severe incontinence have more access to artificial sphincters; while women, who are the most affected by this pathology, are treated minimally or not at all due to a lack of products adapted to their anatomies. According to a study by IMS Consulting Group, in Western countries, only 3% of all artificial sphincter procedures involved women3.
This is therefore a large market, combined with a truly unmet medical need to date. ARTUS aims at becoming the next standard of care in this market. The total global turnover of this market, in the field of urology, is today estimated at $ 7 billion per year in 2020, with a potential annual growth rate of 26% between 2017-20204.
ARTUS, a promising implant to be launched by 2021 in Europe
Video presentation: https://www.youtube.com/watch?v=-l1W1_sgMiM&feature=youtu.be
Currently in clinical phase with ARTUS, Affluent Medical is planning a first market launch in Europe in 2021.Various studies in technical feasibility, safety, tolerance and efficiency have already been conducted both on animals and in laboratory. ARTUS has been clinically tested in Czech Republic, since February 28, 2018, at the Thomayer Hospital in Prague, under the same conditions as the upcoming study in France. A pivotal CE marking trial, which should involve 35 patients suffering from severe urinary incontinence, is planned for the end of 2018. Affluent Medical is also considering a trial in male patients by the end of 2019.
Completion of enrollment in a feasibility study for KALIOS
The implantation of the device in a fifth and last patient has been performed at the end of May 2018 by Prof. Martin Andreas, Principal Investigator of the study, at the Vienna General Hospital (AKH). The first results of the study, aiming at testing the feasibility and surgical safety of KALIOS, are expected in Q2 2018.
KALIOS can treat both residual postoperative leaks and chronic mitral insufficiency. The size and shape of the implant can be adjusted percutaneously multiple times in the months/years following the surgery, offering patients a personalized surgical treatment.
The European launch of the device is scheduled for the end of 2020, subject to the obtention of the necessary marketing authorizations. It targets a total global market expected to reach $3.5 billion by 2022 and growing at a rate of 35% per year between 2017-2022(5).
About Affluent Medical
Affluent Medical is a new French medtech player with the ambition to become one of the European leaders in the treatment of heart and vascular diseases - which are the leading cause of death throughout the world - and of urinary incontinence today affecting one in four adults, subject to the achievement of complementary steps and obtention of marketing authorization. Affluent Medical is developing innovative, next-generation minimally invasive implants to restore key physiological functions in these areas. The company’s four medical devices are currently in preclinical and clinical validation phases, and a first medical device is expected to be launched by 2020.
Affluent Medical was born in February 2018, from the combination of four technologies drawn from Truffle Capital’s portfolio: KARDIOZIS, KALIOS, EPYGON and ARTUS.
Affluent Medical announced it was planning an initial public offering on the Euronext Growth market in Paris and filed a Document de Base with the Autorité des marchés financiers (AMF) on May 28, 2018, with registration number I. 18-045.
For more information: www.affluentmedical.com
This press release and the information it contains do not constitute an offer to sell or to subscribe, or a solicitation to purchase or subscribe shares in Affluent Medical.
The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.
This press release is a promotional message and not a prospectus in the meaning of Directive 2003/71/EC of the European Parliament and Council dated 4 November 2003, as amended (the “Prospectus Directive”).
This press release does not constitute or form part of an offer of securities or a solicitation for purchase, subscription or sale of securities in the United States. Securities may not be offered, subscribed or sold in the United States without registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”,) and other applicable state securities law, except pursuant to an exemption from registration. Affluent Medical shares have not been and will not be registered under the U.S. Securities Act, and Affluent Medical does not intend to undertake a public offering of its securities in the United States.
With respect to the member states of the European Economic Area other than France (the “Member States”) having implemented the Prospectus Directive into law, no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in one of such Member States. As a result, the securities of Affluent Medical may not and will not be offered in any Member State other than France, except in accordance with the exemptions set forth in Article 3 of the Prospectus Directive, if they have been implemented in the relevant member states or in the other case which does not require the publication by Affluent Medical of a prospectus pursuant to the Prospectus Directive and/or applicable regulation in the member states.
This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (1) who are not in the United Kingdom; (2) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”); or (3) who are « high net worth entities », and other persons falling within the provisions of Article 49 (2) (a) to (d) of the Order (those persons cited in (1), (2) and (3) together being designated as “Relevant Persons”).
This press release is aimed solely at Relevant Persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons and may only be made by Relevant Persons.
Not for release, publication or distribution, directly or indirectly, in the United States, Australia, Canada or Japan.
1 Subject to the obtention of necessary marketing
2 ANSM: Agence Nationale de Sécurité du Médicament et des produits de santé
3 Source: IMS Consulting Group Study - 2014: US Market Opportunity Assessment for ARTUS
4 Source: Boston Scientific, Presentation Investor Day 2017, June 27 2017
5 Azoth Analytics – 2017: Transcatheter Mitral Valve Repair and Replacement (TMVR) Market – Opportunities and Forecast 2017-2022
Henri Lefebvre, Chief Financial Officer
Caroline Carmagnol & Wendy Rigal
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF Recognized by SAM’s 2019 “Industry Mover” Sustainability Award15.2.2019 21:15:00 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), was recognized for its sustainability efforts with the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing environmental, social and governance (ESG) data, benchmarks and ratings. The recognition acknowledges the Company’s top-scoring performance in economic, social and environmental categories. “We are thrilled to receive this award from SAM,” said Andreas Fibig, IFF Chairman & CEO. “Our sustainability efforts are not only a key enabler of our overall strategy, but also a true passion here at IFF -- and we place it at the forefront of everything we do. It is deeply gratifying to have our work and our people recognized for doing the right thing for the planet.” SAM’s 2019 scoring is based on its 2018 Corporate Sustainability Assessment. Using a weighted methodology, SAM evaluates companies for criteria such as: codes of business conduct, ope
SFL: strong financial position and results in 2018, consolidating the Group’s position as a prime player15.2.2019 18:01:00 | Pressemelding
Regulatory News: The financial statements for the year ended 31 December 2018 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 15 February 2019 at a meeting chaired by Juan José Brugera. 2018 business indicators were very robust, with further underlying growth in rental income and historically high EPRA earnings. The portfolio's appraisal value and the Company's net asset value also continued to grow, attesting to SFL’s excellent positioning. The auditors have completed their audit of the annual financial information and are in the process of issuing their report. Consolidated data (€ millions) 2018 2017 Change Rental income 193.5 195.8 -1.2% Adjusted operating profit* 162.1 164.1 -1.2% Attributable net profit 351.6 685.3 - EPRA earnings 106.7 102.4 +4.1% * Operating profit before disposal gains and losses and fair value adjustments 31/12/2018 31/12/2017 Change Attributable equity 4,010 3,763 +6.6% Consolidated portfolio value excluding transfer cost
5 Happening Cultural Destinations to Visit in 201915.2.2019 10:11:00 | Pressemelding
Hong Kong There’s never really a sleepy year to visit Hong Kong, but 2019 is particularly ripe for visitors. Spearheaded by the dynamic entrepreneur Adrian Cheng of K11 and New World Development, the rejuvenation of Tsim Sha Tsui harbourfront is just the starting point. The city’s iconic harbourside walkway, Avenue of Stars, has just received a much-awaited makeover that’s the brainchild of Cheng and visually conceived by James Corner, the landscape architect responsible for the High Line in New York. It sees the addition of design-driven rest areas, kiosks featuring homegrown brands, hand prints from Asian film stars and interactive digital elements. Featuring Hong Kong’s first wave energy demonstrator that produces electricity for the Avenue, the place is turned into one of the most sustainable promenades in Hong Kong. This is just one part of Cheng and his company’s grander urban revitalisation plan, Victoria Dockside, a new art and design district which will fully open in the third
ISAE-SUPAERO Launches a New MOOC about Flight Mechanics15.2.2019 09:36:00 | Pressemelding
"ABC of Flight Mechanics: How Do Planes Fly?": a MOOC dedicated to flight mechanics. The notion of flight often defies our human terrestrial instincts. How does an airplane fly? How can a pilot maintain control? How high in the sky can an aircraft climb? How does a fighter pilot fly while spinning? This online course (available in English) will cover many topics, such as atmospheric physics and Newton's laws applied to aircraft, as well as propulsion forces and longitudinal stability the question of traction. The MOOC "ABC of Flight Mechanics" is aimed at general public with a specific level of scientific knowledge. Nevertheless, various levels of learning are available, thus it allows all students to take the course without needing to plenty understand the mathematical principles. Undergraduate students in aerospace engineering, trainees as well as novice and experienced pilots, journalists and professionals in the aeronautics domain (business, engineering, marketing, communications,
REPLY: Red Reply Wins the Oracle “Partner of the Year Autonomous” Award15.2.2019 09:30:00 | Pressemelding
Red Reply, the Reply group company that specialises in the Oracle Cloud IaaS and PaaS platform has been named as Oracle “Partner of the Year: Autonomous.” The award recognises Red Reply for its work as an Oracle Cloud Managed Service Provider Partner in developing highly innovative projects using the Oracle Autonomous Database technology. Red Reply has launched a project aimed at re-engineering the Policy Enterprise DataWarehouse of Verti Assicurazioni, company operating in the online insurance sector, using the Oracle Cloud Autonomous DataWarehouse service. The Autonomous DataWarehouse is a cloud-based database that uses machine learning to eliminate manual labour in operations such as tuning, security, backups, updates and other routine activities. This selected Oracle solution is the only one of its kind capable of addressing aspects such as security, performance and high availability of data, using automatic update and tuning mechanisms, while maximising the protection of data in l
Posiflex showcases new Interactive Self-Service Kiosks and IoT Retail Product Innovations at EuroCIS 201915.2.2019 08:00:00 | Pressemelding
The Posiflex Group — a synergy of world-leading POS, kiosk, and industrial computing technologies — will introduce its full product portfolio and latest innovations at EuroCIS, the leading trade fair for retail technology, from February 19th – 21st in Düsseldorf. With a product strategy focus on serviced IoT, the Posiflex Group will be displaying smart and connected retail solutions with fully-integrated middleware, RMS (Remote Monitoring System) and hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190215005008/en/ Posiflex at EuroCIS Hall 9 / C42 (Graphic: Business Wire) “I am excited to introduce the Posiflex Group portfolio to the European market,” says Hans Peter Nüdling, the newly appointed Chief Strategy Officer for the Posiflex Group. “The Posiflex Group references the collective brands of the corporation, including Posiflex, Portwell and KIOSK Information Systems (KIOSK) – all under one corporate umbrella. As